Despite encouraging preclinical data suggesting that CDK4/6i may improve tumor immunogenicity via multiple mechanisms, including the promotion of antigen presentation and T-cell activation, the suppression of Treg proliferation, and an increase in PD-L1 expression, clinical combinations with ICIs have not yielded meaningful results so far [39]. The gene discussed is CDK4; the disease is neoplasm.